Ranking Profile - Kiniksa Pharmaceuticals Ltd

Introduction

Kiniksa Pharmaceuticals Ltd (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company's pipeline product portfolio includes Rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company has an operational presence in Massachusetts and California, the US; and London, the UK. Kiniksa is headquartered in Hamilton, Bermuda.